Results 71 to 80 of about 37,073 (238)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib.

open access: yesOncoTargets and therapy, 2019
Fibroblast growth factor receptor (FGFR) family includes four highly conserved receptor tyrosine kinases. Particularly, FGFR2 has been identified as a potential target for tyrosine kinase inhibitor (TKI) treatment. Except for immunohistochemistry and fluorescence in situ hybridization, next-generation sequencing (NGS) technology represents a novel tool
Ying, Xihui   +5 more
openaire   +2 more sources

532 Evaluating fibroblast growth factor receptor (FGFR) pathway mRNA expression and protein activation in cholangiocarcinoma tumors

open access: yesJournal of Clinical and Translational Science
Objectives/Goals: Personalized cancer therapy based on genomic testing is advancing patient care. Genomic alterations in fibroblast growth factor receptor (FGFR) predict response to FGFR inhibitors; however, the role of RNA expression and protein ...
Leah Stein   +9 more
doaj   +1 more source

Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma

open access: yesBMC Research Notes, 2020
Objective Fibroblast growth factor receptor (FGFR) 2 regulates the development of the adrenal gland in mice. In addition, FGFR2-mediated signalling has been shown to prevent apoptosis and to enhance proliferation in adrenocortical precursor cells.
Matthias Haase   +5 more
doaj   +1 more source

Membrane lipid metabolism as a regulatory frontier in neural crest biology: Roles for sphingolipids, cholesterol, and lipid rafts

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Neural crest cells are multipotent, migratory stem‐like cells essential for vertebrate development that contribute broadly to many tissues including the craniofacial skeleton, peripheral nervous system, and pigment‐producing cells. Their development progresses through phases of induction, specification, delamination, migration, and ...
Allison E. Mancini   +2 more
wiley   +1 more source

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

open access: yesScientific Reports
FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (
Giovanni Brandi   +15 more
doaj   +1 more source

Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis

open access: yesPharmaceuticals, 2023
Liver fibrosis represents a significant health hazard with a high morbidity rate and an increased risk of liver cancer. Targeting overactivated Fibroblast growth factor receptor 2 (FGFR2) is a promising strategy to counteract collagen accumulation during
Qilin Meng   +13 more
doaj   +1 more source

Novel FGFR2 fusion genes in NCI-H716 colorectal cancer cell line

open access: yes, 2014
Novel FGFR2 fusion genes in NCI-H716 colorectal cancer cell line. The following novel fusion genes have been found in the NCI-H716 colorectal cancer cell line using FusionCatcher: COL14A1-FGFR2, FGFR2-COL14A1, PVT1-FGFR2, TATDN1-DEPTOR, MTSS1-COL14A1 ...
Daniel Nicorici (101429)
core   +1 more source

Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells [PDF]

open access: yes, 2007
Gene amplification and protein overexpression of fibroblast growth factor receptor 2 (FGFR2) characterize the SUM-52 breast cancer cell line developed in our laboratory. SUM-52 cells express nine distinct alternatively spliced isoforms of FGFR2.
Ethier, Stephen P., Moffa, Allison B.
core   +1 more source

Germline Cancer Predisposition and De Novo Contributions in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Approximately 6%–8% of children and adolescents with rhabdomyosarcoma (RMS) have an underlying cancer predisposition disorder (CPD), which varies between embryonal and alveolar subtypes and other clinical characteristics. Identifying a CPD remains challenging, as traditional approaches rely on clinical features and family history. Additionally,
Taylor M. Luckie   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy